FRANCE – September 27, 2023 - The Tour de France 2023 has been a thrilling journey, filled with memorable moments and remarkable victories. From Jonas Vingegaard's stunning triumph to Pogacar's fierce battles and the impressive performance of UK brothers Adam and Simon Yates, the race has been an adventure for cycling enthusiasts worldwide. Amidst the excitement, ProtonDx's Dragonfly Respiratory Panel, a portable, accurate, and rapid diagnostic device, played a pivotal role in maintaining the health and performance of UK team members throughout the Tour. 

​

​

Detecting Health with Precision: 

Dr Jim Kerss, Sports Medicine Lead at the UK Sports Institute, was at the forefront of efforts to ensure the well-being of team members during their journey through France. The Tour de France demands quick decisions and immediate health assessments, and this is where Dragonfly, with its rapid testing capabilities, came to the rescue. The device can detect five respiratory viruses, including SARS-CoV-2, Influenza A (IAV), Influenza B (IAB), Respiratory Syncytial Virus (RSV), and Human rhinovirus (HRV) simultaneously in less than 30 minutes, allowing Dr Kerss and his team to make informed decisions and develop precise health plans for the athletes. 

​

"Portability and ease of use of the device were key given the daily need to follow the tour and travel around France," commented Dr Kerss. Cycling's fast-paced nature requires flexibility, and Dragonfly's lightweight and user-friendly design made it an indispensable tool in the medical arsenal of the UK team. 

​

​

Innovation for Peak Performance: 

ProtonDx's commitment to innovation and portability was evident in Dragonfly's performance during the Tour de France 2023. This partnership underscores the importance of cutting-edge healthcare technology in the world of professional sports, allowing athletes to push their limits while focusing on their health.